We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

STZ:NYSEConstellation Brands, Inc. Analysis

Data as of 2026-03-10 - not real-time

$150.09

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Constellation Brands is trading just above a solid support level near $144, with the 20‑day SMA at $155 and the 50‑day SMA at $154, indicating the price is currently below its short‑term averages. RSI sits in the low‑40s, suggesting neutral momentum, while the MACD line remains below the signal line, producing a bearish histogram. Beta is low at roughly 0.4, which dampens market‑wide swings, but 30‑day volatility is high at nearly 37%, reflecting sizable price swings. Volume trends are decreasing, adding a liquidity drag to the technical picture. On the fundamentals side, revenue has contracted by about 10% year‑over‑year, yet operating and profit margins remain healthy above 30% and 11% respectively, backed by strong cash generation. The balance sheet shows a high debt‑to‑equity ratio exceeding 130%, but free cash flow comfortably covers dividend payouts, supporting a 2.7% yield. A discounted cash‑flow model values the stock around $97, implying the market price carries roughly a 14% premium, while analyst consensus remains bullish with a median target near $166. Recent corporate news highlights a leadership transition and an aggressive expansion of the Pacifico and Victoria beer lines, which could re‑ignite top‑line growth. Overall, the stock sits at the intersection of defensive dividend appeal and overvaluation pressures, with short‑term technical weakness offset by medium‑term growth catalysts.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • price below 20‑day and 50‑day SMAs
  • bearish MACD divergence
  • decreasing volume trend

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • analyst consensus buy with median target ~166
  • strong dividend yield and sustainable payout ratio
  • stable operating margins and robust cash flow

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • low beta reinforces defensive positioning
  • high debt load and volatility pose risk
  • strategic brand expansion (Pacifico/Victoria) may drive future growth

Key Metrics & Analysis

Financial Health

Revenue Growth-9.80%
Profit Margin11.83%
P/E Ratio23.5
ROE14.45%
ROA8.80%
Debt/Equity133.29
P/B Ratio3.4
Op. Cash Flow$2.7B
Free Cash Flow$2.0B

Technical Analysis

TrendBullish
RSI43.5
Support$144.61
Resistance$167.63
MA 20$155.27
MA 50$154.32
MA 200$152.75
MACDBearish
VolumeDecreasing
Fear & Greed Index76.91

Valuation

Fair Value$96.72
Target Price$170.73
Upside/Downside13.75%
GradeOvervalued
TypeValue
Dividend Yield2.74%

Risk Assessment

Beta0.40
Volatility36.99%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.